References

  1. Sandberg H, Kannicht C, Stenlund P, et al. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII. Thromb Res 2012; 130:808-817.
  2. Casademunt E, Martinelle K, Jemberg M, et al. The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics. Eur J Haematol 2012; 89:165-176.
  3. Kannicht C, Ramstrom M, Kohla G, et al. Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII. Thromb Res 2013; 131:78-88.
  4. Valentino LA, Negrier C, Kohla G, et al. The first recombinant FVIII produced in human cells–an update on its clinical development programme. Haemophilia 2014; 20: 1-9.
  5. Kessler C, Oldenburg J, Escuriola Ettingshausen C, et al. Spotlight on the human factor: building a foundation for the future of haemophilia A management. Haemophilia 2015; 21:1-12.
  6. Winge S, Yderland L, Kannicht C, et al. Development, upscaling and validation of the purification process for human-cl rhFVIII (Nuwiq), a new generation recombinant factor VIII produced in a human cell-line. Protein Expression and Purification 2015; 115:165-175.
  7. NUWIQ Full Prescribing Information. Hoboken, NJ: Octapharma USA, Inc.; 2015.
  8. Data on file. Hoboken, NJ: Octapharma USA Inc; 2015.